Holen Sie sich die Stockscreener-App
35.12
6.70%
-2.52
Handel nachbörslich:
35.12
Schlusskurs vom Vortag:
$37.64
Offen:
$37.6
24-Stunden-Volumen:
717.74K
Relative Volume:
0.93
Marktkapitalisierung:
$714.40M
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-24.05
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
-0.31%
1M Leistung:
-21.03%
6M Leistung:
+55.67%
1J Leistung:
+4,521%
1-Tages-Spanne:
$34.90
$38.47
1-Wochen-Bereich:
$33.40
$39.43
52-Wochen-Spanne:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
35.12 | 765.66M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.81 | 119.38B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.63 | 81.46B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
820.31 | 52.65B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 46.50B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.00 | 38.95B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Therapeutics is trying to stage a comeback. But a big test awaits - statnews.com
Nektar Therapeutics (NKTR): A Bull Case Theory - Insider Monkey
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $118 - 富途牛牛
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NKTR Stock News - Longbridge
Where Nektar Therapeutics Stands With Analysts - Benzinga
Nektar Therapeutics (NASDAQ:NKTR) Earns "Buy" Rating from BTIG Research - MarketBeat
NEKTAR THERAPEUTICS Enters Quiet Period for REZOLVE-AD Study - TradingView
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Piper Sandler reiterates Overweight rating on Nektar Therapeutics stock By Investing.com - Investing.com Nigeria
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
Nektar Therapeutics (NKTR) Scheduled for January 28 Meeting - GuruFocus
Piper Sandler reiterates Overweight rating on Nektar Therapeutics stock - Investing.com
Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data' - StreetInsider
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Nektar Therapeutics’ chief R&D officer sells $137,935 in stock By Investing.com - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - yourwyominglink.com
Nektar Therapeutics (NASDAQ:NKTR) Trading 7% HigherHere's Why - MarketBeat
Emerald Mutual Fund Advisers Trust Invests $13.27 Million in Nektar Therapeutics $NKTR - MarketBeat
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $137,935.89 in Stock - MarketBeat
Nektar Therapeutics’ chief R&D officer sells $137,935 in stock - Investing.com
Emerald Advisers LLC Takes Position in Nektar Therapeutics $NKTR - MarketBeat
NK Cell Therapy Market 2034: 7MM Outlook, 30+ Active Developers, IND/NDA Momentum, and Next-Gen CAR-NK Innovations Driving Immunotherapy Advances | DelveInsight - Barchart.com
What Recent Price Target Signals For The Evolving Nektar Therapeutics (NKTR) Story - Yahoo Finance
Nektar Therapeutics: Share Price Dislocation Masks Rezpeg’s Underappreciated Atopic Dermatitis and Alopecia Areata Upside - TipRanks
Corvus pill shows promise in early-stage eczema trial - statnews.com
Bond Watch: Should I buy Nektar Therapeutics stock nowJuly 2025 Technicals & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aug Fed Impact: Should I buy Nektar Therapeutics stock nowMarket Performance Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Nektar Therapeutics Stock Defies Short Sellers with Sharp Rally - AD HOC NEWS
Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation - MSN
Short Interest in Nektar Therapeutics (NASDAQ:NKTR) Rises By 52.3% - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Trading Up 6.9%Still a Buy? - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Stock Price Down 6.7%What's Next? - MarketBeat
History Review: Is Nektar Therapeutics stock a value trapTrade Entry Summary & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Why the JP Morgan conference is important — but not make-or-break - statnews.com
BTIG maintains Nektar Therapeutics (NKTR) buy recommendation - MSN
Ignore Nektar Therapeutics stock in 2026 and load up on this one instead - MSN
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 2025Trade Performance Summary & Step-by-Step Trade Execution Guides - ulpravda.ru
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
Q1 EPS Estimate for Nektar Therapeutics Raised by Analyst - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving AverageHere's What Happened - MarketBeat
Here's why Nektar Therapeutics (NKTR) is a great momentum stock to buy - MSN
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
2.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):